Spotify Pulls Down Curtains On Spotify Live, Highlights Struggle With Live Audio

Spotify Technology S.A. (NYSE: SPOT) is shutting down its live-audio app Spotify Live, a company spokesperson confirmed on Monday.  The company says it will continue to explore live features on its central platform.
  • Spotify Technology S.A. (NYSE:SPOT) is shutting down its live-audio app Spotify Live, a company spokesperson confirmed on Monday. 
  • The company says it will continue to explore live features on its central platform.
  • After a period of experimentation, Spotify decided to sunset the Spotify Live app, a spokesperson told TechCrunch. 
  • Based on its learnings, it no longer makes sense as a standalone app, highlighting the company’s struggle with live audio. 
  • Also Read: Spotify’s Profitability Likely To Breakeven Driven By Subscription Pricing Power And Expense Discipline, Analysts Say
  • Spotify highlighted promising results in the artist-focused use case of ‘listening parties,’ which it will explore.
  • In April 2022, Spotify integrated the live audio capabilities from its companion app, Spotify Greenroom, within the main Spotify streaming app and rebranded Greenroom as “Spotify Live.”
  • Spotify acquired the app christening it Greenroom in March 2021 with its $62 million purchase of the startup Betty Labs. Known initially as Locker Room, the app focused on live audio’s intersection with sports content. 
  • Spotify rebranded the app and introduced it as Greenroom in June 2021. 
  • However, Greenroom failed to gain traction after Spotify rolled out weekly live shows.
  • Last December, Spotify scaled back its live audio ambitions by ending production of several of its live audio shows, including “Deux Me After Dark,” “Doughboys: Snack Pack,” “The Movie Buff,” and “A Gay in the Life.”
  • Meta Platforms Inc (NASDAQ:META) has discontinued its short-form audio Soundbites feature and Audio hub.
  • Price Action: SPOT shares are trading lower by 2.07% at $133.62 premarket on the last check Tuesday.
Total
0
Shares
Related Posts
Read More

Aptar Awarded U.S. FDA Contract To Study Opportunities For Low Global Warming Potential Propellants For Metered Dose Inhalers; The Contracted Work, Including “Optional Contract Line Items”, Is Valued At Up To ~ $6M

AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, is announcing a contract with the U.S. Food and Drug Administration (FDA) to study the challenges

ATR